Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06588283 · ClinicalTrials.gov registry record · Phase 3
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
A Phase 3 study of Obesity and Psoriasis, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 3
- Development phase
- 250
- Enrollment target
- 20
- Study locations
NCT06588283 is a Phase 3 study of Obesity and Psoriasis that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 250 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (69% lower). The trial reports 20 study locations across 5 states.
The verdict
NCT06588283, a Phase 3 study of Obesity and Psoriasis, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 250 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to demonstrate that when participants with moderate to severe plaque psoriasis and obesity or overweight in the presence of at least 1 weight-related comorbid condition receive ixekizumab and tirzepatide concomitantly administered, participants see improvement in their psoriasis and achieve weight reduction compared to when receiving ixekizumab. Participation in this study includes up to 12 visits and could last up to 61 weeks including screening, open label treatment period, and post-treatment follow-up period.
Interventions
- DRUG Tirzepatide
- DRUG Ixekizumab
Study Locations (20)
California
- California Dermatology & Clinical Research Institute - Encinitas
- First OC Dermatology Research Inc - Fountain Valley
- Avance Clinical Trials - Laguna Niguel
- Metropolis Dermatology - Los Angeles
- Dermatology Research Associates - Los Angeles
- Northridge Clinical Trials - Northridge
- Cura Clinical Research - Oxnard - Oxnard
- Integrative Skin Science and Research - Location 2 - Sacramento
- Therapeutics Clinical Research - San Diego
Florida
- Life Clinical Trials - Coral Springs
- Alliance for Multispecialty Research, LLC - Fort Myers
- NeoClinical Research - Hialeah
- Skin Care Research - Hollywood
- Encore Medical Research - Hollywood
- Solutions Through Advanced Research - Jacksonville
Arizona
- Medical Dermatology Specialists - Phoenix
- Scottsdale Clinical Trials - Scottsdale
- Yuma Clinical Trials - Yuma
Alabama
- Total Skin & Beauty Dermatology Center, PC DBA Total Dermatology - Birmingham
Arkansas
- Johnson Dermatology - Fort Smith
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2024-09-30 |
| Est. Completion | 2026-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06588283
The ClinicalTrials.gov registry entry for NCT06588283 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (69% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Tirzepatide is the first listed.
NCT06588283 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT06588283 about?
NCT06588283 is a clinical study titled "Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight". The main purpose of this study is to demonstrate that when participants with moderate to severe plaque psoriasis and obesity or overweight in the presence of at least 1 weight-related comorbid condition receive ixekizumab and tirzepatide concomitantly administered, participants see improvement in th...
What is the current status of trial NCT06588283?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 250 participants. The study started on 2024-09-30. Estimated completion is 2026-05.
What conditions does trial NCT06588283 study?
This clinical trial studies the following conditions: Obesity, Psoriasis.
What interventions are being tested in trial NCT06588283?
The interventions under investigation include: Tirzepatide (DRUG), Ixekizumab (DRUG).
Who is sponsoring clinical trial NCT06588283?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06588283 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
RECRUITING · Phase 3
-
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
RECRUITING · Phase 3
-
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.